Abeona Therapeutics Inc ((ABEO)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Abeona Therapeutics Inc is conducting a Phase 3b clinical study titled A Phase 3b Study for the Treatment of Dystrophic Epidermolysis Bullosa (DEB) in New and Previously EB-101 Treated Patients. This study aims to evaluate the safety of EB-101, a gene-corrected keratinocyte sheet, in treating large, chronic DEB wounds in patients aged 12 months and older. This research is significant as it seeks to improve treatment options for DEB, a severe skin condition.
The intervention being tested is EB-101, a biological treatment involving the surgical application of gene-corrected keratinocyte sheets to DEB wounds. This treatment is designed to promote healing in patients with this challenging condition.
The study is interventional, with a single-group model and no masking, focusing on treatment as its primary purpose. The open-label design allows for direct observation of the treatment’s effects on participants.
The study began on April 2, 2023, and is currently active but not recruiting. The primary completion and estimated completion dates are set for June 24, 2025, which is also the date of the last update. These dates are crucial for tracking the study’s progress and anticipating results.
This update from Abeona Therapeutics could influence the company’s stock performance and investor sentiment positively, as advancements in DEB treatment may enhance Abeona’s market position. Investors should also consider the competitive landscape, as developments in similar treatments could impact market dynamics.
The study is ongoing, with further details available on the ClinicalTrials portal.